Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04287621 · ClinicalTrials.gov registry record
Registry of Asthma Patients Initiating DUPIXENT®
A clinical trial of Asthma, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- 718
- Enrollment target
- 20
- Study locations
NCT04287621 is a study of Asthma that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 718 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT04287621, a study of Asthma, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 718 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: * Patient demographics (eg, gender, age, and race) * Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: * To characterize real-world use patterns of DUPIXENT® for asthma * To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting * To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® * To collect long-term safety data on study participants in the real-world setting
Conditions Studied
Interventions
- DRUG DUPIXENT®
Study Locations (20)
Florida
- Global Research Solutions - Hollywood
- Memorial Healthcare System - Hollywood
- Clinical Research Specialists, LLC - Kissimmee
- Kratz Allergy & Asthma - Port Richey
- GCP, Global Clinical Professionals - St. Petersburg
- Allergy & Asthma Diagnostic Treatment Center - Tallahassee
California
- Children's Hospital of Orange County - Orange
- Riviera Allergy Medical Center - Redondo Beach
- Allergy & Asthma Medical Group and Research, A PC - San Diego
- Bensch Clinical Research, LLC - Stockton
- Allianz Research Institute, Inc. - Westminster
Georgia
- Omni Allergy - Atlanta
- Columbus Regional Research Institute - Columbus
- IACT Health Southeast Lung Associates - Rincon
Arizona
- Arizona Allergy & Immunology Research - Gilbert
- Medical Research of Arizona, a Division of Allergy, Asthma & Immunology Associates, Ltd. - Scottsdale
Illinois
- Northwestern Medical Group Allergy & Immunology Clinic - Chicago
- The University of Chicago - Chicago
Alabama
- Clinical Research Center of Alabama, LLC - Birmingham
Idaho
- Treasure Valley Medical Research - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 718 participants |
| Start Date | 2020-03-02 |
| Est. Completion | 2026-04-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04287621
The ClinicalTrials.gov registry entry for NCT04287621 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 718 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (54% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which DUPIXENT® is the first listed.
NCT04287621 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04287621 about?
NCT04287621 is a clinical study titled "Registry of Asthma Patients Initiating DUPIXENT®". The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: * Patient demographics (eg, gender, age, and race) * Patient...
What is the current status of trial NCT04287621?
This trial is currently active not recruiting. The enrollment target is 718 participants. The study started on 2020-03-02. Estimated completion is 2026-04-27.
What conditions does trial NCT04287621 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT04287621?
The interventions under investigation include: DUPIXENT® (DRUG).
Who is sponsoring clinical trial NCT04287621?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04287621 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.